Document is current

Any future updates will be listed below

Stable disease, diagnosis and dose are prognostic factors for survival after interleukin-2 immunotherapy

Crossref DOI link: https://doi.org/10.1186/2051-1426-3-S2-P138

Published Online: 2015-11-04

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark